Third Arc Bio, Inc.
1 additional officer or director
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- $52Mannounced
Announced a Series A ($52M round) on 4 Feb 2026.
A company that just raised has fresh capital, a new board and new vendors to choose.
FactPress release wires (PR Newswire, GlobeNewswire)For Investors, lenders, service providersFinancing history → - 2 investorsnamed
2 investors on record.
The investors already on the cap table shape who leads the next round.
- 4 directorsboard
4 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
- Feb 4, 2026Series A Extension · $52.0M (disclosed)Fact Press release · “Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio”
- Jul 16, 2024Form D equity offering · $72.5M (form d sold) · 32 investorsOmega Fund Management, LLC via Otello (nmn) StampacchiaFact Form D · “Third Arc Bio, Inc. filed Form D: $72,499,974 sold of $164,999,939, Biotechnology”
- Omega Fund Management, LLC portfolio listing Fact omegafunds.com
- Omega Fund Management, LLC form d related, Otello (nmn) Stampacchia (strongly supported) Inference sec.gov
- Vida Ventures Management board only, Arjun Goyal (strongly supported) Inference sec.gov
Listed on 1 firm portfolio page; none states an outcome (acquired, public, exited or active). DFX does not assume the company is active.
Evidence: 1 listingeach firm's own card, as read
- Status not stated on Omega Fund Management, LLC · the firm's card prints no outcome · read Sep 13, 2026 omegafunds.com“Third Arc Bio”
- Joseph Erhardt Executive Officer sec.gov
- Peter Lebowitz Executive Officer/Director sec.gov
- Arjun Goyal Director Fact
- Arjun Goyal Director Inference
- Otello Stampacchia Director Fact
- Feb 4, 2026Third Arc Bio announced Series A Extension of $52,000,000Round announced Fact Press release
- Aug 1, 2024Third Arc Bio, Inc. filed Form D: $72,499,974 sold of $164,999,939, BiotechnologyForm D filed Fact Form D
Every observation on this company
- Entity type: Corporation Aug 1, 2024 Fact Form D
- Form D industry group: Biotechnology Aug 1, 2024 Fact Form D
- Amendment: false Aug 1, 2024 Fact Form D
- Revenue range (Form D): Decline to Disclose Aug 1, 2024 Fact Form D
- Incorporated: withinFiveYears Aug 1, 2024 Fact Form D
- Jurisdiction: Delaware Aug 1, 2024 Fact Form D
- Amount sold (Form D): $72.5M Aug 1, 2024 Fact Form D
- Offering amount (Form D): $165M Aug 1, 2024 Fact Form D
- Exemptions: 06b Aug 1, 2024 Fact Form D
- First sale: 2024-07-16 Aug 1, 2024 Fact Form D
- Investors (Form D): 32 Aug 1, 2024 Fact Form D
- Minimum investment (Form D): 0 Aug 1, 2024 Fact Form D
- Securities offered: equity Aug 1, 2024 Fact Form D
- Office address: Aug 1, 2024 Fact Form D
- Listed on portfolio page: Omega Fund Management, LLC Sep 13, 2026 Fact Firm website
- Round announced: Series A Extension $52,000,000 Feb 4, 2026 Fact Press release
- Year of incorporation: 2021 Aug 1, 2024 Fact Form D
Relationships across DFX
on 1 other DFX graph
Third Arc Bio, Inc. is the same institution as 1 record in Private Equity.
The joined record opens with the product, beside every other relationship on this page.
Checking your plan…
Record history
- Event retracted2026-09-30
- Portfolio entry removed2026-09-16source on record
- Round announced2026-02-04source on record
+1 more change on this record's ledger
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.